Table 1.
Mechanisms, concepts, and paradigms: commonalities in toxicity, pathophysiology, and pharmacology of cardio-oncology and COVID-19.
| Common topic of study | Cardio-oncology | COVID-19 |
|---|---|---|
| Mechanisms of left ventricular cardiomyopathy | Elucidate mechanisms and optimal management of left ventricular systolic dysfunction in Cardio-Oncology | Elucidate mechanisms and optimal management of left ventricular systolic dysfunction in COVID-19 |
| Immune system activation | Analyze pathophysiology and optimal management of immune response, cytokine release syndrome, and autoimmune adverse effects from ICIs or CAR-T cell therapy | Analyze pathophysiology and optimal management of immune response, cytokine release syndrome, and related adverse effects in COVID-19 |
| Long-term sequelae of inflammation | Investigate long-term implications of inflammation induced by neoplastic agents | Investigate long-term implications of myocardial inflammation in COVID-19 |
| Endothelial dysfunction | Interrogate role of endothelial dysfunction in ischemic and cardiomyopathic cardiovascular injuries from cancer drugs | Interrogate role of endothelial dysfunction in ischemic and cardiomyopathic cardiovascular injuries from COVID-19 |
| Coagulopathy and anticoagulation | Study the burden, mechanisms, and optimal management of coagulopathy (arterial or venous) with need for anticoagulation or antiplatelet therapy in Cardio-Oncology | Study the burden, mechanisms, and optimal management of coagulopathy and microthrombosis with beneficial response to anticoagulation in COVID-19 |
| Role of RV and RVAD | Explore significance of RV systolic dysfunction after anthracycline therapy | Explore significance of RV systolic dysfunction in severe COVID-19 infection |
| Prognostic value of RV strain | Evaluate utility of RV strain to predict outcomes following anthracycline therapy | Evaluate utility of RV strain to predict COVID-19 severity/mortality |
| Utility of steroid therapy and biologics | Determine the effectiveness and timing of steroid treatment and monoclonal antibodies for inflammation- or immune-related adverse events from ICIs or CAR-T cells | Determine the effectiveness and timing of steroid treatment and monoclonal antibodies for inflammation-related adverse CV events in COVID-19 |
| Neurohormonal therapy | Establish cardioprotective contributions of neurohormonal therapies | Establish whether neurohormonal therapies are protective in COVID-19 |
| Potential drug Interactions | Appraise the extent and impact of potential drug interactions between Cardiology drugs and Oncology drugs | Appraise the extent and impact of potential drug interactions between Cardiology drugs and COVID-19 drugs |
| Impact of health disparities | Assess underlying factors and solutions to address health disparities in cardiovascular toxicities observed in Cardio-Oncology | Assess underlying factors and solutions to address health disparities observed in cardiovascular injuries in COVID-19 |
| Precision of risk prediction | Develop precise methods of predicting cardiovascular toxicities and prognosis | Develop precise methods of predicting risk and overall prognosis in COVID-19 |
CAR-T Cells, Chimeric Antigen Receptor T-Cells; COVID-19, Coronavirus Diseases of 2019; CV, cardiovascular; ICI, Immune Checkpoint Inhibitor; RV, Right Ventricle; RVAD, Right Ventricular Assist Device.